Biphasic Mesothelioma

Biphasic mesothelioma cancer derives its name from the fact that it manifests both epithelioid and sarcomatoid mesothelioma cells. This form of the disease is not identified with any one cellular structure but rather with the two types of cells that between them constitute over 95% of all mesothelioma diagnoses. Exactly how the two cellular components come together isn't clear ‚Äď it's possible that asbestos fibers lodged in both the pleural mesothelium, and in some form of connective tissue in a location around the lungs or in the peritoneal cavity (the abdomen). Epithelial cells are by far the most common cause of mesothelioma, generating up to 70% of all cases. Sarcomatoid-cell mesothelioma is relatively rare, found in 7% - 10% of all diagnoses. The biphasic condition when both cell types are present represents up to 25% % of all mesothelioma cases.

Biphasic Mesothelioma Characteristics

The two cancer cell types found in this disease differ in shape and size and in patterns of behavior. Sarcomatoid cells tend to be more active, to produce other malignant cells at a greater pace and to spread at a quicker rate than epithelioid mesothelioma cells. Sarcomatoid mesothelioma is the most aggressive form of the disease and the most difficult to treat. Epithelial cells do not reproduce as rapidly as the sarcomatoid cells, but with biphasic mesothelioma both cell types must be treated simultaneously in order to attempt to slow the growth of the malignancy.

There are some interesting characteristics to biphasic manifestations of this disease. The epithelioid and sarcomatoid cells are not necessarily intermingled, but may well be grouped with like cells in separate locations within the diseased tissue. Biphasic mesothelioma may have malignant epithelial cells in one portion of the membrane and a sarcomatoid tumor in the lung itself, or sarcomatoid cells in another portion of the mesothelium.
The fact that mesothelioma is a diffuse cancer rather than one concentrated in tumors (sarcomas) means that a biopsy might find the malignant epithelial cells to be expected in mesothelioma and miss sarcomatoid cells located elsewhere. One of the reasons that the diagnosis of biphasic mesothelioma may have risen in recent years is the practice of multiple biopsies to determine the spread of this complicated disease.

Treatment of Biphasic Mesothelioma

Clinical tests have found certain chemotherapy drugs to be effective against one cell and ineffective against the other. That is one reason why so many malignant mesothelioma cases are treated with chemotherapy 'cocktails' comprised of multiple chemo drugs and radiation therapy as well.

The National Cancer Institute maintains a database of all clinical trials being conducted for cancer. There are over 6,000 of them and there are at one hundred that are focused solely on mesothelioma. Many are concentrated on pleural mesothelioma but that does not preclude targeting both epithelioid and sarcomatoid cancer cells, although more conservative physicians see no effective treatment for mesothelioma that involves sarcomatoid cells, other than palliative.

In fact several researchers are experimenting with using the drug pemetrexed along with other established chemotherapy drugs such as cisplatin to determine how best to choke off the growth of mesothelioma cancer cells. Some cells are effectively destroyed by an enzyme, for example, while others are unaffected. This suggests that the trials are taking into account the possibility of biphasic mesothelioma as an important aspect of the disease.

Sources:

  1. Malignant Mesothelioma, American Cancer Society, http://www.cancer.org/downloads/pub/docs/section28/89.pdf
  2. ClinicalTrials.gov, National Institutes of Health, http://clinicaltrials.gov/ct/search?term=%22malignant+mesothelioma%22
  3. Malignant Peritoneal Mesothelioma…Triple Combined Therapy, National Library of Medicine, NIH, http://www.ncbi.nlm.nih.gov/pubmed/17306123

Attorney sponsoring this site is licensed in Washington DC Flood Law Office, LLP - 1101 Pennsylvania Avenue NW, Suite 600, Washington, DC, 20004

Copyright © 2003-2014 Asbestos News